<!DOCTYPE html>
        <html lang="en">
        <head>
          <meta charset="UTF-8" />
          <meta name="viewport" content="width=device-width, initial-scale=1.0" />
          <title>MinMaxMuscle | Retatrutide</title>
          <meta name="description" content="Curated source summaries for Retatrutide." />
          <link rel="stylesheet" href="../assets/css/style.css" />
        </head>
        <body>
          <header>
            <div class="nav-container">
              <div class="logo">
                <img src="../assets/img/logo.png" alt="MinMaxMuscle Logo" />
                <span>MINMAXMUSCLE</span>
              </div>
              <nav class="desktop-nav">
                <a href="../index.html">Home</a>
                <a href="../training.html">Training</a>
                <a href="../nutrition.html">Nutrition</a>
                <a href="../peptides.html">Peptides</a>
                <a href="../coaching.html">Coaching</a>
                <a href="../contact.html">Contact</a>
              </nav>
              <div class="hamburger" id="hamburger">
                <span></span>
                <span></span>
                <span></span>
              </div>
            </div>
            <div class="mobile-menu" id="mobileMenu">
              <a href="../index.html">Home</a>
              <a href="../training.html">Training</a>
              <a href="../nutrition.html">Nutrition</a>
              <a href="../peptides.html">Peptides</a>
              <a href="../coaching.html">Coaching</a>
              <a href="../contact.html">Contact</a>
            </div>
          </header>
          <main>
            <section class="hero">
              <h1>Retatrutide</h1>
              <p>Automated source summaries for educational review. Verify claims with qualified professionals.</p>
            </section>
            <section class="peptide-source">
  <h2>Source</h2>
  <p><a href="https://en.wikipedia.org/wiki/Retatrutide" rel="noopener noreferrer" target="_blank">https://en.wikipedia.org/wiki/Retatrutide</a></p>
  <ul>
    <li>Main page</li><li>Contents</li><li>Current events</li><li>Random article</li><li>About Wikipedia</li><li>Contact us</li><li>Help</li><li>Learn to edit</li><li>Community portal</li><li>Recent changes</li><li>Upload file</li><li>Special pages</li><li>Donate</li><li>Create account</li><li>Log in</li><li># Contents</li><li>(Top)</li><li>1 Clinical trials</li><li>2 Chemistry</li><li>3 Research</li><li>4 See also</li><li>5 References</li><li># Retatrutide</li><li>Deutsch</li><li>Italiano</li><li>Polski</li><li>Русский</li><li>Українська</li><li>中文</li><li>Article</li><li>Talk</li><li>Read</li><li>Edit</li><li>View history</li><li>What links here</li><li>Related changes</li><li>Permanent link</li><li>Page information</li><li>Cite this page</li><li>Get shortened URL</li><li>Download QR code</li><li>Download as PDF</li><li>Printable version</li><li>Wikimedia Commons</li><li>Wikidata item</li><li>L -tyrosyl-2-methylalanyl- L -glutaminylglycyl- L -threonyl- L -phenylalanyl- L -threonyl- L -seryl- L -α-aspartyl-L-tyrosyl-L-seryl- L -isoleucyl-2-methyl- L -leucyl- L -leucyl- L -α-aspartyl- L -lysyl- N 6 -( N -(19-carboxy-1-oxononadecyl)- L -γ-glutamyl-2-(2-(2-aminoethoxy)ethoxy)acetyl)- L -lysyl- L -alanyl- L -glutaminyl-2-methylalanyl- L -alanyl- L -phenylalanyl- L -isoleucyl- L -α-glutamyl- L -tyrosyl- L -leucyl- L -leucyl- L -α-glutamylglycylglycyl- L -prolyl- L -seryl- L -serylglycyl- L -alanyl- L -prolyl- L -prolyl- L -prolyl- L -serinamide</li><li>2381089-83-2</li><li>NOP2Y096GV</li><li>ChEMBL5095485</li><li>CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C)NC(=O)C(C)(C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@](C)(CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O</li><li>InChI=1S/C221H342N46O68/c1-23-124(11)179(208(322)241-144(83-88-176(291)292)192(306)245-150(105-134-69-75-137(276)76-70-134)196(310)244-148(100-121(5)6)194(308)243-147(99-120(3)4)193(307)240-142(82-87-175(289)290)187(301)230-110-169(282)229-113-173(286)264-92-51-61-161(264)206(320)253-158(116-270)203(317)251-157(115-269)189(303)232-111-170(283)233-128(15)212(326)266-94-53-63-163(266)214(328)267-95-54-64-164(267)213(327)265-93-52-62-162(265)207(321)250-156(114-268)183(226)297)258-200(314)152(103-131-55-41-39-42-56-131)242-185(299)127(14)235-216(331)219(18,19)262-205(319)145(80-85-166(225)279)237-184(298)126(13)234-190(304)140(60-48-50-90-227-172(285)119-335-98-97-334-96-91-228-167(280)86-81-146(215(329)330)236-168(281)65-45-37-35-33-31-29-27-25-26-28-30-32-34-36-38-46-66-174(287)288)238-191(305)141(59-47-49-89-222)239-198(312)154(107-177(293)294)247-195(309)149(101-122(7)8)256-218(333)221(22,109-123(9)10)263-211(325)180(125(12)24-2)259-204(318)160(118-272)252-197(311)151(106-135-71-77-138(277)78-72-135)246-199(313)155(108-178(295)296)248-202(316)159(117-271)254-210(324)182(130(17)274)260-201(315)153(104-132-57-43-40-44-58-132)249-209(323)181(129(16)273)257-171(284)112-231-188(302)143(79-84-165(224)278)255-217(332)220(20,21)261-186(300)139(223)102-133-67-73-136(275)74-68-133/h39-44,55-58,67-78,120-130,139-164,179-182,268-277H,23-38,45-54,59-66,79-119,222-223H2,1-22H3,(H2,224,278)(H2,225,279)(H2,226,297)(H,227,285)(H,228,280)(H,229,282)(H,230,301)(H,231,302)(H,232,303)(H,233,283)(H,234,304)(H,235,331)(H,236,281)(H,237,298)(H,238,305)(H,239,312)(H,240,307)(H,241,322)(H,242,299)(H,243,308)(H,244,310)(H,245,306)(H,246,313)(H,247,309)(H,248,316)(H,249,323)(H,250,321)(H,251,317)(H,252,311)(H,253,320)(H,254,324)(H,255,332)(H,256,333)(H,257,284)(H,258,314)(H,259,318)(H,260,315)(H,261,300)(H,262,319)(H,263,325)(H,287,288)(H,289,290)(H,291,292)(H,293,294)(H,295,296)(H,329,330)/t124-,125-,126-,127-,128-,129+,130+,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,179-,180-,181-,182-,221-/m0/s1</li><li>Key:MLOLQJNKXBNWFW-JMUPIODPSA-N</li><li>Retatrutide ( LY-3437943 ) is an experimental drug for obesity developed by the American pharmaceutical company Eli Lilly and Company . It is a triple glucagon hormone receptor agonist ( GLP-1 , GIP , and GCGR receptors). [ 1 ] [ 2 ] [ 3 ]</li><li># Clinical trials</li><li>Retatrutide has been studied in a phase 2 trial involving adults without diabetes but with obesity or preobesity (overweight). [ 4 ] [ 5 ] [ 6 ] Retatrutide is also being evaluated in phase 3 clinical trials. [ 7 ] A substudy in adults with type 2 diabetes reported differences in total body fat mass between study groups at 36 weeks. [ 8 ]</li><li>Across clinical studies, the most commonly reported adverse events were gastrointestinal symptoms such as nausea, vomiting, and diarrhea. [ 6 ]</li><li>Preclinical and biochemical studies describe receptor activity at GLP-1, GIP, and glucagon receptors. [ 9 ] Reports on its development state that it was engineered for activity across these targets. [ 1 ]</li><li>Systematic reviews and meta-analyses of randomized controlled trials report that retatrutide produces substantial reductions in body weight in adults with obesity, with mean percentage weight loss typically between 15 and 24 percent over 48 to 72 weeks, depending on study protocols and populations. [ 10 ] [ 11 ] [ 12 ] [ 13 ] [ 14 ] Adverse events are most commonly gastrointestinal symptoms such as nausea and diarrhea , with relatively low rates of study discontinuation and infrequent serious adverse events reported during trials. [ 10 ] [ 11 ] [ 12 ] Safety assessments also indicate a low risk of hypoglycemia and no significant elevation in cardiovascular or hepatic adverse events in non-diabetic populations across published studies. [ 13 ] [ 14 ]</li><li># Chemistry</li><li>Retatrutide is a peptide with the following amino acid sequence [ 15 ]</li><li>YA¹QGTFTSDYSIL²LDKK⁴AQA¹AFIEYLLEGGPSSGAPPPS³</li><li>where letters with superscripted numbers refer to the following chemical modifications:</li><li>A¹ – 2-aminoisobutyric acid (Aib).</li><li>L² – leucine modified with an α-methyl substituent (MeL, 2-methylleucine).</li><li>S³ – L -serinamide ( L - serine with the carboxylic acid group replaced with a carboxamide ).</li><li>K⁴ – L - lysine with the amino group at position 6 modified with a side chain; specifically, (AEEA)-(γ- Glu )-(C20 diacid) (where AEEA is 2-[2-(2-aminoethoxy)ethoxy]acetic acid, commonly used as a spacer group in synthetic peptides).</li><li># Research</li><li>Preclinical studies suggest that retatrutide may influence obesity-associated cancer progression. In a study led by Marathe et al., retatrutide-induced weight loss reduced tumor engraftment, delayed tumor onset, and significantly attenuated tumor growth in pancreatic and lung cancer models, with greater tumor suppression than the GLP-1 receptor agonist semaglutide; antitumor effects persisted despite partial weight regain and were associated with durable systemic and tumor immune reprogramming. [ 16 ]</li><li># See also</li><li>Tirzepatide</li><li>Semaglutide</li><li>Incretin</li><li>Glucagon-like peptide-1 receptor agonist</li><li>Glucagon</li><li># References</li><li>^ a b .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free.id-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited.id-lock-limited a,.mw-parser-output .id-lock-registration.id-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription.id-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-free a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-limited a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-registration a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-subscription a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .cs1-ws-icon a{background-size:contain;padding:0 1em 0 0}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:var(--color-error,#bf3c2c)}.mw-parser-output .cs1-visible-error{color:var(--color-error,#bf3c2c)}.mw-parser-output .cs1-maint{display:none;color:#085;margin-left:0.3em}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}@media screen{.mw-parser-output .cs1-format{font-size:95%}html.skin-theme-clientpref-night .mw-parser-output .cs1-maint{color:#18911f}}@media screen and (prefers-color-scheme:dark){html.skin-theme-clientpref-os .mw-parser-output .cs1-maint{color:#18911f}} Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, et al. (September 2022). "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept" . Cell Metabolism . 34 (9): 1234–1247.e9. doi : 10.1016/j.cmet.2022.07.013 . PMID 35985340 . S2CID 251675508 .</li><li>^ Bhat S, Fernandez CJ, Lakshmi V, Pappachan JM (August 2025). "Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare" . World Journal of Cardiology . 17 (8) 107991. doi : 10.4330/wjc.v17.i8.107991 . PMC 12426997 . PMID 40949933 .</li><li>^ Concepción-Zavaleta MJ, Fuentes-Mendoza JM, Gonzáles-Yovera JG, Ruvalcaba-Barbosa GY, Cura-Rodríguez LD, González-Rodríguez JS, et al. (October 2025). "Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review" . World Journal of Gastroenterology . 31 (37) 111435. doi : 10.3748/wjg.v31.i37.111435 . PMC 12476660 . PMID 41025003 .</li><li>^ "Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight" . investor.lilly.com (Press release). Eli Lilly. 26 June 2023 . Retrieved 3 July 2023 .</li><li>^ Constantino AK (26 June 2023). "Eli Lilly experimental obesity drug could beat rivals in total weight loss for patients" . CNBC .com . Retrieved 3 July 2023 .</li><li>^ a b Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. (August 2023). "Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial". The New England Journal of Medicine . 389 (6): 514– 526. doi : 10.1056/NEJMoa2301972 . PMID 37366315 . S2CID 259260926 . Free access subject to registration.</li><li>^ "A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) - Lilly Clinical Trials" . Lilly Trials . Retrieved 2025-08-24 .</li><li>^ Coskun T, Wu Q, Schloot NC, Haupt A, Milicevic Z, Khouli C, et al. (August 2025). "Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial". The Lancet. Diabetes & Endocrinology . 13 (8): 674– 684. doi : 10.1016/S2213-8587(25)00092-0 . PMID 40609566 .</li><li>^ "Compound: RETATRUTIDE (CHEMBL5095485)" . www.ebi.ac.uk . Retrieved 2025-11-24 .</li><li>^ a b Tewari J, Qidwai KA, Tewari A, Kaur S, Tewari V, Maheshwari A (2025). "Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis". Expert Review of Clinical Pharmacology . 18 ( 1– 2): 51– 66. doi : 10.1080/17512433.2025.2450254 . PMID 39817343 .</li><li>^ a b Abdrabou Abouelmagd A, Abdelrehim AM, Bashir MN, Abdelsalam F, Marey A, Tanas Y, et al. (2025). "Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials" . Proceedings . 38 (3): 291– 303. doi : 10.1080/08998280.2025.2456441 . PMC 12026077 . PMID 40291085 .</li><li>^ a b Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K (May 2025). "Retatrutide-A Game Changer in Obesity Pharmacotherapy" . Biomolecules . 15 (6): 796. doi : 10.3390/biom15060796 . PMC 12190491 . PMID 40563436 .</li><li>^ a b Olowo-Oribi BA, Salway RJ (November 2025). "Efficacy of Tirzepatide, Retatrutide, and Semaglutide for Weight Loss in Obese Individuals Without Diabetes". Academic Emergency Medicine . 32 (11): 1255– 1258. doi : 10.1111/acem.70088 . PMID 40583149 .</li><li>^ a b Sinha B, Ghosal S (November 2025). "Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA". Obesity . 33 (11): 2046– 2054. doi : 10.1002/oby.24360 . PMID 40685589 .</li><li>^ "Retatrutide" . Compound Report Card . European Bioinformatics Institute , European Molecular Biology Laboratory . n.d . Retrieved August 5, 2024 .</li><li>^ Marathe SJ, Grey EW, Bohm MS, Joseph SC, Ramesh AV, Cottam MA, et al. (2025-03-14). "Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression" . NPJ Metabolic Health and Disease . 3 (1): 10. doi : 10.1038/s44324-025-00054-5 . PMC 11908972 . PMID 40094000 .</li><li>v</li><li>t</li><li>e</li><li>Insulin aspart</li><li>Insulin glulisine</li><li>Insulin lispro</li><li>Regular insulin #</li><li>Insulin detemir #</li><li>Insulin glargine # ( +lixisenatide )</li><li>NPH insulin</li><li>Lente insulin ‡</li><li>Ultralente insulin ‡</li><li>Insulin degludec # ( +insulin aspart , +liraglutide )</li><li>Insulin icodec † ( +semaglutide )</li><li>Exubera ‡</li><li>Afrezza</li><li>Insulin tregopil †</li><li># WHO-EM</li><li>‡ Withdrawn from market</li><li>† Phase III</li><li>§ Never to phase III</li><li>Buformin ‡</li><li>Metformin #</li><li>Phenformin ‡</li><li>Ciglitazone §</li><li>Darglitazone §</li><li>Englitazone §</li><li>Lobeglitazone</li><li>Netoglitazone §</li><li>Pioglitazone</li><li>Rivoglitazone †</li><li>Rosiglitazone</li><li>Troglitazone ‡</li><li>Aleglitazar †</li><li>Muraglitazar §</li><li>Saroglitazar</li><li>Tesaglitazar §</li><li>Cagrilintide §</li><li>Pramlintide</li><li>1st generation: Acetohexamide</li><li>Carbutamide</li><li>Chlorpropamide</li><li>Glycyclamide</li><li>Metahexamide</li><li>Tolazamide</li><li>Tolbutamide</li><li>2nd generation: Glibenclamide (glyburide)</li><li>Glibornuride</li><li>Glicaramide</li><li>Gliclazide #</li><li>Glimepiride</li><li>Glipizide</li><li>Gliquidone</li><li>Glisoxepide</li><li>Glyclopyramide</li><li>Mitiglinide</li><li>Nateglinide</li><li>Repaglinide</li><li>Albiglutide ‡</li><li>Danuglipron †</li><li>Dulaglutide</li><li>Exenatide</li><li>Liraglutide</li><li>Lixisenatide</li><li>Orforglipron †</li><li>Taspoglutide †</li><li>Mazdutide (GLP-1/ GCGR )</li><li>Retatrutide § (GLP-1/GIP/GCGR)</li><li>Tirzepatide (GLP-1/GIP)</li><li>Alogliptin</li><li>Anagliptin</li><li>Evogliptin</li><li>Garvagliptin</li><li>Gemigliptin</li><li>Gosogliptin</li><li>Linagliptin</li><li>Melogliptin</li><li>Omarigliptin</li><li>Retagliptin</li><li>Saxagliptin</li><li>Sitagliptin</li><li>Teneligliptin</li><li>Trelagliptin</li><li>Vildagliptin</li><li>Epalrestat</li><li>Fidarestat §</li><li>Ranirestat †</li><li>Tolrestat ‡</li><li>Zenarestat §</li><li>Acarbose</li><li>Miglitol</li><li>Voglibose</li><li>Canagliflozin</li><li>Dapagliflozin</li><li>Empagliflozin #</li><li>Ertugliflozin</li><li>Ipragliflozin</li><li>Luseogliflozin</li><li>Remogliflozin §</li><li>Sergliflozin §</li><li>Sotagliflozin</li><li>Tofogliflozin †</li><li>Velagliflozin</li><li>Benfluorex ‡</li><li>Bromocriptine</li><li>Imeglimin</li><li>Alogliptin/metformin</li><li>Canagliflozin/metformin</li><li>Cagrilintide/semaglutide §</li><li>Dapagliflozin/metformin</li><li>Dapagliflozin/saxagliptin</li><li>Dapagliflozin/saxagliptin/metformin</li><li>Empagliflozin/linagliptin</li><li>Empagliflozin/metformin</li><li>Gemigliptin/rosuvastatin</li><li>Glibenclamide (glyburide)/metformin</li><li>Glimepiride/rosiglitazone</li><li>Linagliptin/metformin</li><li>Metformin/acarbose</li><li>Metformin/ertugliflozin</li><li>Metformin/evogliptin</li><li>Metformin/gemigliptin</li><li>Metformin/repaglinide</li><li>Metformin/sulfonylureas</li><li>Metformin/teneligliptin</li><li>Phenformin/sulfonylureas</li><li>Pioglitazone/alogliptin</li><li>Pioglitazone/glimepiride</li><li>Pioglitazone/metformin</li><li>Pioglitazone/sitagliptin</li><li>Rosiglitazone/metformin</li><li>Saxagliptin/metformin</li><li>Sitagliptin/dapagliflozin</li><li>Sitagliptin/ertugliflozin</li><li>Sitagliptin/metformin</li><li>Sitagliptin/simvastatin</li><li>Vildagliptin/metformin</li><li>GLP-1 receptor agonists</li><li>Peptide therapeutics</li><li>GIP receptor agonists</li><li>Glucagon receptor agonists</li><li>Lipopeptides</li><li>Articles with short description</li><li>Short description matches Wikidata</li><li>Short description is different from Wikidata</li><li>Infobox drug articles with non-default infobox title</li><li>Chemical pages without ChemSpiderID</li><li>Chemical pages without DrugBank identifier</li><li>Articles without KEGG source</li><li>Chemical articles having Jmol set</li><li>Chemical articles having Jmol set/None</li><li>Drugs missing an ATC code</li><li>Drugs with no legal status</li><li>Articles containing unverified chemical infoboxes</li><li>This page was last edited on 11 January 2026, at 09:54 (UTC) .</li><li>Text is available under the Creative Commons Attribution-ShareAlike 4.0 License ; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy . Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. , a non-profit organization.</li><li>Privacy policy</li><li>Disclaimers</li><li>Contact Wikipedia</li><li>Legal & safety contacts</li><li>Code of Conduct</li><li>Developers</li><li>Statistics</li><li>Cookie statement</li><li>Mobile view</li>
  </ul>
</section>
<section class="peptide-source">
  <h2>Source</h2>
  <p><a href="https://clinicaltrials.gov/search?cond=&term=Retatrutide" rel="noopener noreferrer" target="_blank">https://clinicaltrials.gov/search?cond=&term=Retatrutide</a></p>
  <ul>
    <li>Study record managers: refer to the Data Element Definitions if submitting registration or results information.</li><li>Search for terms</li>
  </ul>
</section>
<section class="peptide-source">
  <h2>Source</h2>
  <p><a href="https://pubchem.ncbi.nlm.nih.gov/compound/Retatrutide" rel="noopener noreferrer" target="_blank">https://pubchem.ncbi.nlm.nih.gov/compound/Retatrutide</a></p>
  <ul>
    <li># JavaScript is required...</li><li>Please enable Javascript in order to use PubChem website.</li>
  </ul>
</section>
            <p class="disclaimer-link"><small>Back to the main peptide list: <a href="../peptides.html">Peptides Overview</a>.</small></p>
          </main>
          <footer>
            © MinMaxMuscle. Discipline builds the body. Systems keep it.
          </footer>
          <script src="../assets/js/script.js"></script>
        </body>
        </html>
